Impoyz is a drug owned by Primus Pharmaceuticals Inc. It is protected by 4 US drug patents filed from 2018 to 2020 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 11, 2035. Details of Impoyz's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9855334 | Topical compositions comprising a corticosteroid |
Mar, 2035
(10 years from now) | Active |
| US10064875 | Topical formulations comprising a steroid |
Aug, 2030
(5 years from now) | Active |
| US10588914 | Topical formulations comprising a steroid |
Aug, 2030
(5 years from now) | Active |
| US9956231 | Topical formulations comprising a steroid |
Aug, 2030
(5 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Impoyz's patents.
Latest Legal Activities on Impoyz's Patents
Given below is the list of recent legal activities going on the following patents of Impoyz.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 18 Sep, 2023 | US10588914 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 04 Mar, 2022 | US10064875 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 01 Nov, 2021 | US9956231 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 02 Jul, 2021 | US9855334 |
| Email Notification Critical | 26 Apr, 2021 | US10588914 |
| Change in Power of Attorney (May Include Associate POA) Critical | 26 Apr, 2021 | US10588914 |
| Correspondence Address Change Critical | 22 Apr, 2021 | US10588914 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 22 Apr, 2021 | US10588914 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 21 Apr, 2021 | US10064875 |
| Email Notification Critical | 21 Apr, 2021 | US10064875 |
FDA has granted several exclusivities to Impoyz. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Impoyz, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Impoyz.
Exclusivity Information
Impoyz holds 1 exclusivities. All of its exclusivities have expired in 2020. Details of Impoyz's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 28, 2020 |
US patents provide insights into the exclusivity only within the United States, but Impoyz is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Impoyz's family patents as well as insights into ongoing legal events on those patents.
Impoyz's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Impoyz's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 11, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Impoyz Generic API suppliers:
Clobetasol Propionate is the generic name for the brand Impoyz. 35 different companies have already filed for the generic of Impoyz, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Impoyz's generic
How can I launch a generic of Impoyz before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Impoyz's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Impoyz's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Impoyz -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.00025 | 06 Dec, 2019 | 1 | 11 Mar, 2035 |
Alternative Brands for Impoyz
Impoyz which is used for treating moderate to severe plaque psoriasis in patients 18 years of age or older., has several other brand drugs in the same treatment category and using the same active ingredient (Clobetasol Propionate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Clobetasol Propionate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Eyenovia |
| ||
| Norvium Bioscience |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Clobetasol Propionate, Impoyz's active ingredient. Check the complete list of approved generic manufacturers for Impoyz
About Impoyz
Impoyz is a drug owned by Primus Pharmaceuticals Inc. It is used for treating moderate to severe plaque psoriasis in patients 18 years of age or older. Impoyz uses Clobetasol Propionate as an active ingredient. Impoyz was launched by Primus Pharms in 2017.
Approval Date:
Impoyz was approved by FDA for market use on 28 November, 2017.
Active Ingredient:
Impoyz uses Clobetasol Propionate as the active ingredient. Check out other Drugs and Companies using Clobetasol Propionate ingredient
Treatment:
Impoyz is used for treating moderate to severe plaque psoriasis in patients 18 years of age or older.
Dosage:
Impoyz is available in cream form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.025% | CREAM | Prescription | TOPICAL |